Convallatoxin

Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties[1][2][3].

Product Specifications

CAS Number

[508-75-8]

UNSPSC

12352005

Hazard Statement

H301+H311+H331

Target

NF-κB; P-glycoprotein; PPAR

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/convallatoxin.html

Purity

99.72

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1OCC([C@H]2CC[C@]3(O)[C@]4([H])CC[C@]5(O)C[C@@H](O[C@H]6[C@@H]([C@@H]([C@H]([C@H](C)O6)O)O)O)CC[C@]5(C=O)[C@@]4([H])CC[C@]23C)=C1

Molecular Formula

C29H42O10

Molecular Weight

550.64

Precautions

H301+H311+H331

References & Citations

[1]Li MY, et al. Convallatoxin protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB signaling through activation of PPARγ. Pharmacol Res. 2019 Sep;147:104355.|[2]Gozalpour E, et al. Convallatoxin: a new P-glycoprotein substrate. Eur J Pharmacol. 2014 Dec 5;744:18-27.|[3]Chao PK, et al. Convallatoxin enhance the ligand-induced mu-opioid receptor endocytosis and attenuate morphine antinociceptive tolerance in mice. Sci Rep. 2019 Feb 20;9 (1) :2405.|[4]Jiang BW, et al. Convallatoxin induces HaCaT cell necroptosis and ameliorates skin lesions in psoriasis-like mouse models. Biomed Pharmacother. 2020 Jan;121:109615.